Funding and related issue pertaining to primary immunodeficiency disease.
H.R. 3017, the PI Post Acute Access Act and policies pertaining to access to immunoglobulin (Ig) treatments for Medicare beneficiaries within Skilled Nursing Facilities
FY 25 report language pertaining to primary immunodeficiency disease medical research.
Duration: February 1, 2020
to
present
General Issues: Health Issues , Medicare/Medicaid , Budget/Appropriations
Spending: about $400,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2020: U.S. Senate, House of Representatives, Natl Institutes of Health (NIH), Centers For Medicare and Medicaid Services (CMS), Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Homeland Security - Dept of (DHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Nicholas Manetto Press Secretary and Legislative Assistant, Rep. Christopher H. Smith (R-NJ)
Megan Herber Legislative Director/Senior Legislative Assistant/Legislative Assistant, Rep. Doris Matsui (D-CA)
Nisha Quasba n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Faegre Drinker Biddle & Reath LLP lobbied for Immune Deficiency Foundation , earning $30,000. The report was filed on April 19.
Original Filing: 301565270.xml
Lobbying Issues
Funding and related issue pertaining to primary immunodeficiency disease.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 3017, the PI Post Acute Access Act and policies pertaining to access to immunoglobulin (Ig) treatments for Medicare beneficiaries within Skilled Nursing Facilities
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 25 report language pertaining to primary immunodeficiency disease medical research.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Faegre Drinker Biddle & Reath LLP lobbied for Immune Deficiency Foundation , earning $30,000. The report was filed on Jan. 17.
Original Filing: 301527162.xml
Lobbying Issues
Opportunities to increase funding to support research into primary immunodeficiency diseases; H.R. 830 and S. 1375, the HELP Copays Act; Proposed FDA rule re: Laboratory Developed Test and implications for the PI community.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 3017, the PI Post Acute Access Act and policies pertaining to access to immunoglobulin (Ig) treatments for Medicare beneficiaries within Skilled Nursing Facilities; implementation of permanent Medicare in-home IVIG bundled payment.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Faegre Drinker Biddle & Reath LLP lobbied for Immune Deficiency Foundation , earning $20,000. The report was filed on Oct. 17, 2023.
Original Filing: 301502789.xml
Lobbying Issues
Opportunities to increase funding to support research into primary immunodeficiency diseases; H.R. 830 and S. 1375, the HELP Copays Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 3017, the PI Post Acute Access Act and policies pertaining to access to immunoglobulin (Ig) treatments for Medicare beneficiaries within Skilled Nursing Facilities; implementation of permanent Medicare in-home IVIG bundled payment.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Faegre Drinker Biddle & Reath LLP lobbied for Immune Deficiency Foundation , earning $30,000. The report was filed on July 19, 2023.
Original Filing: 301483117.xml
Lobbying Issues
Opportunities to increase funding to support research into primary immunodeficiency diseases; H.R. 830 and S. 1375, the HELP Copays Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 3017, the PI Post Acute Access Act and policies pertaining to access to immunoglobulin (Ig) treatments for Medicare beneficiaries within Skilled Nursing Facilities; implementation of permanent Medicare in-home IVIG bundled payment.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Faegre Drinker Biddle & Reath LLP lobbied for Immune Deficiency Foundation , earning $30,000. The report was filed on April 17, 2023.
Original Filing: 301452433.xml
Lobbying Issues
Support for research into primary immunodeficiencies including reporting on such research
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Lobbying Issues
Implementation of permanent in-home IVIG services payment. Policies pertaining to access to immunoglobulin therapies for Medicare beneficiaries with primary immunodeficiencies when admitted to SNFs.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Faegre Drinker Biddle & Reath LLP lobbied for Immune Deficiency Foundation , earning $30,000. The report was filed on Jan. 19, 2023.
Original Filing: 301433121.xml
Lobbying Issues
FY 23 appropriations and policies pertaining to research into primary immunodeficiencies and public health activities focused on immunocompromised persons.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the public health emergency of relevance to the immunocompromised population.
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Lobbying Issues
Sec. 4134 of Omnibus Appropriations Act, permanent in-home benefit for IVIG services.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Faegre Drinker Biddle & Reath LLP lobbied for Immune Deficiency Foundation , earning $20,000. The report was filed on Oct. 20, 2022.
Original Filing: 301414761.xml
Lobbying Issues
FY 23 appropriations and policies pertaining to research into primary immunodeficiencies and public health activities focused on immunocompromised persons.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the public health emergency of relevance to the immunocompromised population.
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Lobbying Issues
Policies pertaining to beneficiary access to immunoglobulin therapy in the home and in skilled nursing facilities; treatment of blood plasma products as part of any Medicare drug negotiation program.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Faegre Drinker Biddle & Reath LLP lobbied for Immune Deficiency Foundation , earning $20,000. The report was filed on July 20, 2022.
Original Filing: 301388782.xml
Lobbying Issues
FY 23 appropriations and policies pertaining to research into primary immunodeficiencies and public health activities focused on immunocompromised persons.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the public health emergency of relevance to the immunocompromised population.
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Lobbying Issues
Policies pertaining to beneficiary access to immunoglobulin therapy in the home and in skilled nursing facilities.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Faegre Drinker Biddle & Reath LLP lobbied for Immune Deficiency Foundation , earning $20,000. The report was filed on April 18, 2022.
Original Filing: 301359098.xml
Lobbying Issues
Advocacy pertaining to immunoglobulin therapies and drug pricing provisions included in the Build Back Better Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the public health emergency of relevance to the immunocompromised population.
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Lobbying Issues
Access to Ig therapies for Medicare beneficiaries.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Faegre Drinker Biddle & Reath LLP lobbied for Immune Deficiency Foundation , earning $20,000. The report was filed on Jan. 18, 2022.
Original Filing: 301325588.xml
Lobbying Issues
Advocacy pertaining to immunoglobulin therapies and drug pricing provisions included in the Build Back Better Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues pertaining to the immunocompromised community related to the COVID-19 pandemic; Issues pertaining to plasma donation and collection; Issues pertaining to plasma collection and donation involving Mexican Nationals.
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Lobbying Issues
Ongoing engagement on policies pertaining to in-home intravenous immunoglobulin therapy.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Faegre Drinker Biddle & Reath LLP lobbied for Immune Deficiency Foundation , earning $20,000. The report was filed on Oct. 20, 2021.
Original Filing: 301312939.xml
Lobbying Issues
FY 2022 appropriations for HRSA SCID newborn screening program and plasma protein education and awareness activities.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues pertaining to the immunocompromised community related to the COVID-19 pandemic; Issues pertaining to plasma donation and collection; Issues pertaining to plasma collection and donation involving Mexican Nationals.
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
2nd Quarter, 2021
In Q2, Faegre Drinker Biddle & Reath LLP lobbied for Immune Deficiency Foundation , earning $20,000. The report was filed on July 20, 2021.
Original Filing: 301290299.xml
Lobbying Issues
FY 2022 appropriations for HRSA SCID newborn screening program and plasma protein education and awareness activities.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issuance of final DME rule pertaining to access to home infusion drugs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues pertaining to the immunocompromised community related to the COVID-19 pandemic; Issues pertaining to plasma donation and collection.
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
1st Quarter, 2021
In Q1, Faegre Drinker Biddle & Reath LLP lobbied for Immune Deficiency Foundation , earning $20,000. The report was filed on April 14, 2021.
Original Filing: 301252839.xml
Lobbying Issues
FY22 appropriations for HRSA SCID newborn screening program and plasma protein education and awareness activities.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issuance of final DME rule pertaining to access to home infusion drugs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues pertaining to the immunocompromised community related to the COVID-19 pandemic.
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
4th Quarter, 2020
In Q4, Faegre Drinker Biddle & Reath LLP lobbied for Immune Deficiency Foundation , earning $30,000. The report was filed on Jan. 13, 2021.
Original Filing: 301230365.xml
Lobbying Issues
Fiscal Year 2021 Labor, HHS Appropriations Act provisions focused on IVIG bundled payment demonstration and HRSA newborn screening
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 7839 - Continuing Access to In-Home IVIG Act; S. 3457, H.R. 6218 - Preserving Patient Access to Home Infusion Act; COVID-19 response and beneficiary access to home infusion care as a result of the PHE.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Faegre Drinker Biddle & Reath LLP lobbied for Immune Deficiency Foundation , earning $30,000. The report was filed on Oct. 19, 2020.
Original Filing: 301215057.xml
Lobbying Issues
Fiscal Year 2021 Labor, HHS Appropriations Act provisions focused on IVIG bundled payment demonstration and HRSA newborn screening
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 7839 - Continuing Access to In-Home IVIG Act; S. 3457, H.R. 6218 - Preserving Patient Access to Home Infusion Act; COVID-19 response and beneficiary access to home infusion care as a result of the PHE.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Faegre Drinker Biddle & Reath LLP lobbied for Immune Deficiency Foundation , earning $20,000. The report was filed on July 17, 2020.
Original Filing: 301192218.xml
Lobbying Issues
Fiscal Year 2021 Labor, HHS Appropriations Act provisions focused on IVIG bundled payment demonstration and HRSA newborn screening
Agencies Lobbied
U.S. Senate
Lobbying Issues
Access to in-home IVIG including extension of CMS IVIG Bundled Payment Demonstration; S. 3457, H.R. 6218 - Preserving Patient Access to Home Infusion Act; COVID-19 response and beneficiary access to home infusion care as a result of the PHE.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Faegre Drinker Biddle & Reath LLP lobbied for Immune Deficiency Foundation , earning $10,000. The report was filed on April 19, 2020.
Original Filing: 301172323.xml
Lobbying Issues
Fiscal Year 2021 Labor, HHS Appropriations Act provisions focused on access to care and SCID newborn screening
Agencies Lobbied
U.S. Senate
Lobbying Issues
Access to in-home IVIG including around current IVIG Bundled Payment Demonstration; S. 3457, H.R. 6218 - Preserving Patient Access to Home Infusion Act; COVID-19 response and beneficiary access to care as a result of the emergency
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
Faegre Drinker Biddle & Reath LLP filed a lobbying registration on April 17, 2020 to represent Immune Deficiency Foundation, effective Feb. 1, 2020.
Original Filing: 301169304.xml
Issue(s) they said they’d lobby about: Labor, HHS Appropriations Act provisions focused on access to care and SCID newborn screening; Access to in-home IVIG; COVID-19 response and beneficiary access to care as a result of the emergency .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...